AI-generated summary
The authors report a randomized, double-blind interim analysis of extraoral photobiomodulation or placebo given to head and neck cancer patients receiving radiotherapy, to prevent oral mucositis. Among 55 patients, the authors report that the treated group had delayed mucositis onset, lower pain scores at week 7, fewer analgesic and anti-inflammatory prescriptions, and better quality of life, with no difference in one-year survival. This is an interim analysis, so the findings may change.
- Participants
- 55
- Who or what was studied
- Patients with oral cavity and oropharyngeal squamous cell carcinoma receiving radiotherapy
- Limits stated in the abstract
- This is an interim analysis of a single trial with a small sample of 55 patients, and the abstract reports one year of survival follow-up only.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Visual analogue scale, Trial registration, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.